Currently funded projects

Dr. Giannou (NP, MD, Msc, PhD) im mikrochirurgischen Labor

Einfluss von IL-22 und IL-22BP auf die Lebermetastasierung

Institutions: I. Medizinische Klinik und Poliklinik Universitätsklinikum Hamburg-Eppendorf
Applicant: Anastasios Giannou
EKFS funding line: Else Kröner-Memorial-Stipendium

TaqMan basierte Analyse eines Einzelnukleotid-Polymorphismus im miR-146a Gen

The impact of microRNA-146a on the development of immune related adverse events during immune checkpoint inhibitor therapy

Institution: Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg
Applicant: Natalie Köhler
EKFS funding line: first application

Dr. rer. nat Nadine Gehrke (left) and technician Irina Wagner (right)

Role of hepatic interleukin-1 receptor type 1 (IL-1R1) in inflammatory hepatocarcinogenesis

Institution: I. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz
Applicant: Nadine Gehrke
EKFS funding line: key project

Dr. Engeland (MD PhD) and Dr. Veinalde (PhD) discuss results in the research laboratory at the National Center for Tumor Diseases.

Translational research on combination immunotherapy with an oncolytic vaccine

Institutions: National Center for Tumor Diseases, German Cancer Research Center, University Hospital Heidelberg
Applicant: Dr. med. Dr. rer. nat. Christine E. Engeland
EKFS funding line: Else Kröner-Memorial-Stipendium

Dr. rer. nat. Verena Boschert (left) and Dr. med. Dr. med. dent. Stefan Hartmann (right) working in the lab of the Department of Oral and Maxillofacial Plastic Surgery (University Hospital Würzburg)

Immune escape mechanisms in head and neck squamous cell carcinoma: The role of HGF/Met signalling pathway

Institution: Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg
Applicant: Stefan Hartmann
EKFS funding line: first application

Project vision

Immune diagnostics of an hereditary cancer predisposition syndrome: A functional test for Lynch syndrome?

Institutions: Abteilung für Angewandte Tumor Biologie, Institut für Pathologie, Universitätsklinikum Heidelberg
Applicants: Matthias Kloor, Aysel Ahadova, Magnus von Knebel Doeberitz
EKFS funding line: key project

In vivo high field MRI (left) and ultramicroscopy images (right) of the cleared brain shows the extent of tumor cell infiltration of S24 glioma cells (red). The microvasculature is stained with lectin-FITC (green).

Imaging of immune responses and tumor cell invasion in glioma models

Institution: Universitätsklinik Heidelberg – Deutsches Krebsforschungszentrum
Applicant: Dr. med. Michael Breckwoldt, Ph.D.
EKFS funding line: first application

Research Group Neuroendocrine Tumors (Primary Investigator Dr. S. Nölting)

Characterisation and overcoming mechanisms of resistance to the mTORC1 inhibitor everolimus

Institutions: Research Group NeuroendocrineTumors, Department of Internal Medicine IV, University Hospital of Munich, LMU Munich
Applicant: Dr. Svenja Nölting
EKFS fundig line: first application

Left: Bladder cancer is molecularly diverse. By combination of different methods including high-througput analyses we investigate proteins involved. Right: Dr. F. Dressler, J. Schoenfeld and Biologist O. Revyakina (from left to right)

Tumorspezifische Protein-Signatur des Harnblasenkarzinoms

Institution: Institute of Pathology, University Medical Center Schleswig-Holstein, Luebeck Site
Applicant: Dr. med. Franz F. Dreßler
EKFS funding line: first application